Previous 10 | Next 10 |
Germany's Affimed ( NASDAQ: AFMD ) stock rose ~22% on Thursday after the company said it signed an agreement with San Diego-based Artiva Biotherapeutics to jointly develop and commercialize a combination therapy to treat cancer. The combo therapy consists of Aff...
Companies to combine their clinical programs (AFM13, AB-101) to address high unmet need of CD30-positive lymphoma patients Affimed’s AFM13 in combination with cord blood-derived NK cells demonstrated exceptionally high response rates in relapsed and refractory CD30-positive l...
In 24 patients with CD30-positive lymphoma treated at the highest dose level, the combination treatment of AFM13 with allogeneic NK cells continues to achieve a 100% overall response rate and an improved 70.8% complete response rate Patients received up to four cycles and the trea...
HEIDELBERG, Germany, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Execu...
Summary Two poster presentations showing AFM24 as a monotherapy and combination treatment will be presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer, November 8-12, 2022. Results from the phase 2 registration REDIRECT study using AFM13 as a monotherapy...
Affimed Therapeutics stock ( NASDAQ:AFMD ) appeared ailing in the stock market on Monday. The company’s U.S.-traded shares fell more than 16% as a result of a pretty depressing fresh analyst assessment. So, what’s the deal with Affimed Stock? ...
European biotech Affimed Therapeutics (NASDAQ: AFMD) was looking a bit sickly on our stock exchange Monday. The company's U.S.-traded shares suffered a more than 16% decline, on the back of a rather dispiriting new take from an analyst. The prognosticator in question is Stifel...
Stifel has downgraded Affimed N.V. ( NASDAQ: AFMD ) to hold from buy as the firm no longer believes that three upcoming data updates will be positive for the biotech. Stifel also cut its price target for the biotech to $2 from $9 (5% upside based on Friday's close). An...
A poster evaluating comprehensive correlative science findings from the AFM24 monotherapy phase 1 study (AFM24-101) will be presented In a second poster presentation, initial phase 1 dose escalation study results of AFM24 in combination with Roche’s checkpoint inhibitor atezoli...
Selected recommended phase 2 dose (RP2D) of 480 mg with ongoing enrollment in disease-specific cohorts; maximum tolerated dose (MTD) not reached Stable disease was observed in 10 of 27 evaluable patients in an unselected patient population Comprehensive pharmacodynamic studies ind...
News, Short Squeeze, Breakout and More Instantly...
2024-07-07 08:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-17 17:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...